問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Hematology & Oncology

Division of Urology

更新時間：2023-09-19

洪士鈞
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

7Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

洪士鈞

List

12Cases

2020-10-26 - 2028-06-30

Phase III

Active
A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

  • Condition/Disease

    Metastatic Castration-Sensitive Prostate Cancer

  • Test Drug

    Niraparib

Participate Sites
9Sites

Not yet recruiting1Sites

Recruiting1Sites

Terminated7Sites

2018-10-30 - 2022-12-31

Phase III

Completed
A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations

  • Condition/Disease

    Urothelial Cancer

  • Test Drug

    Erdafitinib

Participate Sites
12Sites

Recruiting2Sites

Terminated10Sites

吳文正
Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital

Division of Urology

2018-02-05 - 2022-12-31

Phase II

Completed
A Phase II, Randomized, Multi-Center, Double-Blind, Comparative Global Study to Determine the Efficacy and Safety of Durvalumab in Combination With Olaparib for First-Line Treatment in Cisplatin-Ineligible Patients With Unresectable Stage IV Urothelial Cancer

  • Condition/Disease

    urothelial cancer

  • Test Drug

    Durvalumab(MEDI4736) Olaparib

Participate Sites
10Sites

Terminated8Sites

Study ended1Sites

馮思中
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

吳文正
Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital

Division of Urology

2018-09-28 - 2026-12-31

Phase III

Active
A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatment Followed by Durvalumab Alone for Adjuvant Treatment in Patients with Muscle-Invasive Bladder Cancer

  • Condition/Disease

    Muscle-Invasive Bladder Cancer

  • Test Drug

    Durvalumab

Participate Sites
8Sites

Recruiting6Sites

Terminated1Sites

2017-09-26 - 2025-06-13

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2020-07-22 - 2025-11-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2018-06-15 - 2022-10-28

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2019-05-19 - 2027-01-25

Phase III

Active
A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy Alone Versus Neoadjuvant Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post- Surgery Therapy With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle- Invasive Bladder Cancer

  • Condition/Disease

    Muscle- Invasive Bladder Cancer

  • Test Drug

    BMS-986205

Participate Sites
4Sites

Recruiting4Sites

2019-06-01 - 2024-07-31

Phase III

A Phase 3, Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Lenvatinib (E7080/MK-7902) Versus Pembrolizumab and Placebo as First Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma in Cisplatin-ineligible Participants Whose Tumors Express PD-L1, and in Participants Ineligible for Any Platinum-containing Chemotherapy Regardless of PD-L1 Expression (LEAP-011)

  • Condition/Disease

    Locally Advanced or Metastatic Urothelial Carcinoma

  • Test Drug

    Lenvatinib Pembrolizumab

Participate Sites
7Sites

Recruiting7Sites

吳文正
Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital

Division of Urology

2018-06-15 - 2021-06-30

Phase III

An Open-Label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin vs. Chemotherapy in Subjects with Previously Treated Locally Advanced or Metastatic Urothelial Cancer(EV-301)

  • Condition/Disease

    Locally Advanced or Metastatic Urothelial Cancer

  • Test Drug

    enfortumab vedotin

Participate Sites
6Sites

Recruiting5Sites

Study ended1Sites

林永昌
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

1 2
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB